- Home
- KPRX vs CAPS Comparison
KPRX vs CAPS Comparison
Compare KPRX & CAPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- CAPS
- Stock Information
- Founded
- KPRX 1998
- CAPS 1987
- Country
- KPRX United States
- CAPS United States
- Employees
- KPRX N/A
- CAPS N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CAPS
- Sector
- KPRX Health Care
- CAPS
- Exchange
- KPRX Nasdaq
- CAPS NYSE
- Market Cap
- KPRX 9.1M
- CAPS 9.8M
- IPO Year
- KPRX N/A
- CAPS N/A
- Fundamental
- Price
- KPRX $2.82
- CAPS $1.42
- Analyst Decision
- KPRX Strong Buy
- CAPS
- Analyst Count
- KPRX 1
- CAPS 0
- Target Price
- KPRX $10.00
- CAPS N/A
- AVG Volume (30 Days)
- KPRX 1.4M
- CAPS 70.8K
- Earning Date
- KPRX 08-08-2025
- CAPS 04-02-2025
- Dividend Yield
- KPRX N/A
- CAPS N/A
- EPS Growth
- KPRX N/A
- CAPS N/A
- EPS
- KPRX N/A
- CAPS N/A
- Revenue
- KPRX $20,000.00
- CAPS $43,416,000.00
- Revenue This Year
- KPRX N/A
- CAPS $7.87
- Revenue Next Year
- KPRX N/A
- CAPS N/A
- P/E Ratio
- KPRX N/A
- CAPS N/A
- Revenue Growth
- KPRX N/A
- CAPS N/A
- 52 Week Low
- KPRX $2.51
- CAPS $1.40
- 52 Week High
- KPRX $4.86
- CAPS $16.18
- Technical
- Relative Strength Index (RSI)
- KPRX 40.86
- CAPS N/A
- Support Level
- KPRX $2.87
- CAPS N/A
- Resistance Level
- KPRX $3.22
- CAPS N/A
- Average True Range (ATR)
- KPRX 0.18
- CAPS 0.00
- MACD
- KPRX -0.03
- CAPS 0.00
- Stochastic Oscillator
- KPRX 21.20
- CAPS 0.00
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About CAPS CAPSTONE HOLDING CORP
Capstone Holding Corp is a building products distribution network. The existing network is comprised of Instone, a distributor of thin veneer stone and related masonry products in the United States, serving both residential and commercial construction markets. The company's product offering includes manufactured and natural stone products, supported by a distribution network. The company's current products include stone veneer, landscape stone, and modular masonry fireplaces.